Should Héroux-Devtek Inc. (TSE:HRX) Be Your Next Stock Pick?

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Héroux-Devtek Inc. (TSE:HRX), it is a company that has been able to sustain great financial health, trading at an attractive share price. Below, I've touched on some key aspects you should know on a high level. For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on Héroux-Devtek here.

Advertisement

Good value with adequate balance sheet

HRX's ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This indicates that HRX has sufficient cash flows and proper cash management in place, which is a crucial insight into the health of the company. HRX's has produced operating cash levels of 0.25x total debt over the past year, which implies that HRX's management has put its borrowings into good use by generating enough cash to cover a sufficient portion of borrowings. HRX is currently trading below its true value, which means the market is undervaluing the company's expected cash flow going forward. This mispricing gives investors the opportunity to buy into the stock at a cheap price compared to the value they will be receiving, should analysts' consensus forecast growth be correct. Compared to the rest of the capital goods industry, HRX is also trading below its peers, relative to earnings generated. This bolsters the proposition that HRX's price is currently discounted.

TSX:HRX Intrinsic value, September 15th 2019
TSX:HRX Intrinsic value, September 15th 2019

Next Steps:

For Héroux-Devtek, there are three relevant factors you should further examine:

  1. Future Outlook: What are well-informed industry analysts predicting for HRX’s future growth? Take a look at our free research report of analyst consensus for HRX’s outlook.
  2. Historical Performance: What has HRX's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of HRX? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About TSX:HRX

Héroux-Devtek

Engages in the design, development, manufacture, and repair and overhaul of aircraft landing gears, hydraulic and electromechanical flight control actuators, custom ball screws, and fracture-critical components.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
37 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
59 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
21 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
19 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AE
ASML logo
Aequitas on ASML Holding ·

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

Fair Value:€1.87k16.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
FTNT logo
Aequitas on Fortinet ·

Fortinet, compounding Cyber Security Player.

Fair Value:US$116.8430.4% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
CSU logo
Aequitas on Constellation Software ·

Constellation Software: A Proven Serial Acquirer at a Discount

Fair Value:CA$3.72k28.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
70 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
70 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
GOOGL logo
tripledub on Alphabet ·

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

Fair Value:US$23039.0% overvalued
92 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

0
|
0